添加普拉克索对帕金森病患者临床疗效及非运动症状的影响观察

Effect of Pramipexole on Clinical Efficacy and Non-motor Symptoms in Patients with Parkinson's Disease

目的分析添加普拉克索对帕金森病患者临床治疗效果的影响以及非运动症状的变化。方法选取该院2017年1—12月期间收治的帕金森患者128例,并依据随机的原则、按照就诊顺序分成实验组(多巴丝肼添加普拉克索治疗)和对照组(多巴丝肼治疗),每组64例,观察两组患者临床疗效以及非运动症状的区别。结果结果显示,实验组患者睡眠时间、睡眠障碍、入睡时间、睡眠效率、日间功能、安眠药物评分分别为(0.65±0.23)分、(0.69±0.21)分、(1.02±0.53)分、(0.53±0.14)分、(0.33±0.06)分、(0.51±0.13)分,均显著优于对照组,差异有统计学意义(t=19.094、21.449、15.387、16.115、12.592、11.475,P=0.012、0.009、0.015、0.019、0.024、0.026<0.05)。对比两组患者治疗后非运动症状异常的变化可以发现,实验组症状改善效率远远大于对照组,差异有统计学意义(P<0.05)。治疗前,实验组患者6 min步行距离为(2.5±0.7)m,对照组患者6 min步行距离为(2.6±0.5)m,两组比较差异无统计学意义(P>0.05);治疗后,实验组患者6 min步行距离为(352.8±11.4)m,对照组患者6 min步行距离为(113.2±14.6)m,实验组显著优于对照组,差异有统计学意义(P<0.05)。结论帕金森患者治疗方案中添加普拉克索能够提高治疗效果,改善非运动症状。

Objective To analyze the effect of pramipexole on the clinical treatment of patients with Parkinson's disease and the changes of non-motor symptoms.Methods A total of 128 patients with Parkinson's disease admitted to our hospital from January 2017 to December 2017 were enrolled.According to the principle of randomization,the patients were divided into experimental group(addition of pramipexole)and control group(Barthol's treatment),64 patients in each group,observed the difference between clinical efficacy and non-motor symptoms in the two groups.Results The sleep time,sleep disturbance,falling sleep time,sleep efficiency,daytime function,and hypnotic drug scores of the experimental group were(0.65±0.23)points,(0.69±0.21)points,(1.02±0.53)points,(0.53±0.14)points,(0.33±0.06)points,(0.51±0.13)points,both significantly better than the control group,the difference was significant(t=19.094,21.449,15.387,16.115,12.592,11.475,P=0.012,0.009,0.015,0.019,0.024,0.026<0.05).Comparing the changes of non-exercise symptoms after treatment in the two groups,the improvement of symptoms in the experimental group was much greater than that in the control group,and the difference was statistically significant(P<0.05).Before treatment,the walking distance of the experimental group was(2.5±0.7)m,and the walking distance of the control group was(2.6±0.5)m.There was no significant difference between the two groups(P>0.05).After treatment,the experimental group walking distance of 6 min was(352.8±11.4)m,and the walking distance of the control group was(113.2±14.6)m.The experimental group was significantly better than the control group,the difference was statistically significant(P<0.05).Conclusion The addition of pramipexole to Parkinson's patients can improve the treatment and improve non-motor symptoms.